1. Smith, RA, Cokkinides, V, Eyre, HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 2007; 57: 90–104.
Google Scholar | Crossref | Medline | ISI2. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7–30.
Google Scholar | Crossref | Medline | ISI3. Stupp, R, Monnerat, C,, Turrisi, AT 3rd, et al. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004; 45: 105–117.
Google Scholar | Crossref | Medline | ISI4. Govindan, R, Page, N, Morgensztern, D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539–4544.
Google Scholar | Crossref | Medline | ISI5. Kalemkerian, GP, Akerley, W, Bogner, P, et al. Small cell lung cancer. J Natl Compr Canc Netw 2013; 11: 78–98.
Google Scholar | Crossref | Medline6. Byers, LA, Rudin, CM. Small cell lung cancer: where do we go from here? Cancer 2015; 121: 664–672.
Google Scholar | Crossref | Medline | ISI7. Rivera, MP, Mehta, AC, Wahidi, MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2013; 143: e142S–e165S.
Google Scholar | Crossref | Medline | ISI8. Nakamura, H, Nishimura, T. History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer. Surg Today 2017; 47: 1037–1059.
Google Scholar | Crossref | Medline9. Plebani, M, Basso, D, Navaglia, F, et al. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 1995; 72: 170–173.
Google Scholar | Crossref | Medline10. Bates, J, Rutherford, R, Divilly, M, et al. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur Respir J 1997; 10: 2535–2538.
Google Scholar | Crossref | Medline11. Jørgensen, LG, Osterlind, K, Genollá, J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres [published correction appears in Br J cancer 1996 Dec;74:2043]. Br J Cancer 1996; 74: 463–467.
Google Scholar | Crossref | Medline | ISI12. Quoix, E, Purohit, A, Faller-Beau, M, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Canc 2000; 30: 127–134.
Google Scholar | Crossref | Medline13. Satoh, H, Ishikawa, H, Kurishima, K, et al. Cut-off levels of NSE to differentiate SCLC from NSCLC. Oncol Rep 2002; 9: 581–583.
Google Scholar | Medline | ISI14. Maruno, K, Yamaguchi, K, Abe, K, et al. Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1989; 49: 629–632.
Google Scholar | Medline15. Dong, A, Zhang, J, Chen, X, et al. Diagnostic value of ProGRP for small cell lung cancer in different stages. J Thorac Dis 2019; 11: 1182–1189.
Google Scholar | Crossref | Medline16. Mauro, C, Passerini, R, Spaggiari, L, et al. New and old biomarkers in the differential diagnosis of lung cancer: pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1. Int J Biol Markers 2019; 34: 163–167.
Google Scholar | SAGE Journals | ISI17. Molina, R, Filella, X, Augé, JM. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 2004; 37: 505–511.
Google Scholar | Crossref | Medline18. Molina, R, Auge, JM, Filella, X, et al. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res 2005; 25: 1773–1778.
Google Scholar | Medline19. Chen, X, Wang, X, He, H, et al. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer. PLoS One 2015; 10: e0126276.
Google Scholar | Crossref | Medline20. Liu, L, Teng, J, Zhang, L, et al. The combination of the tumor markers suggests the histological diagnosis of lung cancer. Biomed Res Int 2017; 2017: 2013989.
Google Scholar | Medline21. Yang, Q, Zhang, P, Wu, R, et al. Identifying the best marker combination in CEA, CA125, CY211, NSE, and SCC for lung cancer screening by combining ROC curve and logistic regression analyses: is it feasible? Dis Markers 2018; 2018: 2082840.
Google Scholar | Crossref | Medline22. Korkmaz, ET, Koksal, D, Aksu, F, et al. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer. Clin Biochem 2018; 58: 15–19.
Google Scholar | Crossref | Medline23. Molina, R, Augé, JM, Bosch, X, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol 2009; 30: 121–129.
Google Scholar | Crossref | Medline24. Molina, R, Marrades, RM, Augé, JM, et al. Assessment of a combined panel of six serum tumor markers for lung cancer. Am J Respir Crit Care Med 2016; 193: 427–437.
Google Scholar | Crossref | Medline25. Molina, R, Auge, JM, Escudero, JM, et al. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol 2008; 29: 371–380.
Google Scholar | Crossref | Medline26. Travis, WD, Brambilla, E, Nicholson, AG, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015; 10: 1243–1260.
Google Scholar | Crossref | Medline | ISI27. Rami-Porta, R, Asamura, H, Travis, WD, et al. Lung cancer - major changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin 2017; 67: 138–155.
Google Scholar | Crossref | Medline28. Antwi, E, Groenwold, RH, Browne, JL, et al. Development and validation of a prediction model for gestational hypertension in a Ghanaian cohort. BMJ Open 2017; 7: e012670.
Google Scholar | Crossref | Medline29. Yang, HJ, Gu, Y, Chen, C, et al. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis. Clin Chem Lab Med 2011; 49: 1039–1046.
Google Scholar | Crossref | Medline30. Buccheri, G, Ferrigno, D. Lung tumour markers in oncology practice: a study of TPA and CA125. Br J Cancer 2002; 87: 1112–1118.
Google Scholar | Crossref | Medline31. Salvati, F, Antilli, A, Cruciani, AR, et al. Plasma carcinoembryonic antigen and tissue polypeptide antigen levels in lung cancer: correlation with cell types and stage. Cancer Detect Prev 1985; 8: 111–114.
Google Scholar | Medline32. Kucera, R, Topolcan, O, Fiala, O, et al. The role of TPS and TPA in the diagnostics of distant metastases. Anticancer Res 2016; 36: 773–777.
Google Scholar | Medline33. Okamura, K, Takayama, K, Izumi, M, et al. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer 2013; 80: 45–49.
Google Scholar | Crossref | Medline | ISI34. Du, Q, Yan, C, Wu, SG, et al. Development and validation of a novel diagnostic nomogram model based on tumor markers for assessing cancer risk of pulmonary lesions: a multicenter study in Chinese population. Cancer Lett 2018; 420: 236–241.
Google Scholar | Crossref | Medline35. Thomas, A, Pattanayak, P, Szabo, E, et al. Characteristics and outcomes of small cell lung cancer detected by CT screening. Chest 2018; 154: 1284–1290.
Google Scholar | Crossref | Medline36. van Klaveren, RJ, Oudkerk, M, Prokop, M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009; 361: 2221–2229.
Google Scholar | Crossref | Medline | ISI